If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-13. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
If {H3O+} increases {CH3CO2H} must increase and CH3CO−2 must decrease. The H2O is left out, as it is the solvent and its concentration remains high and nearly constant. J. W. Gibbs suggested in 1873 that equilibrium is attained when the "available energy" (now known as Gibbs free energy or Gibbs energy) of the system is at its minimum value, assuming the reaction is carried out at a constant temperature and pressure. What this means is that the derivative of the Gibbs energy with respect to reaction coordinate (a measure of the extent of reaction that has occurred, ranging from zero for all reactants to a maximum for all products) vanishes (because dG = 0), signaling a stationary point. This derivative is called the reaction Gibbs energy (or energy change) and corresponds to the difference between the chemical potentials of reactants and products at the composition of the reaction mixture. This criterion is both necessary and sufficient. If a mixture is not at equilibrium, the liberation of the excess Gibbs energy (or Helmholtz energy at constant volume reactions) is the "driving force" for the composition of the mixture to change until equilibrium is reached. The equilibrium constant can be related to the standard Gibbs free energy change for the reaction by the equation
==== Amnion ==== The amnion is avascular, meaning it does not contain its own blood vessels. Therefore, it must obtain necessary nutrients and oxygen from nearby chorionic and amniotic fluid, and fetal surface vessels. The amnion is characterised by cuboidal and columnar epithelial layers. The columnar cells are located in the vicinity of the placenta, whereas the cuboidal cells are found in the periphery. During early pregnancy, the amnionic epithelium is sparsely covered in microvilli, which increase in number throughout pregnancy. The function of this microvillous surface is associated with a densely-packed glycocalix with anionic binding sites; these are thought to be involved with intra-amnionic lipid synthesis. This amnionic epithelium is connected to a basement membrane, which is then attached by filaments to a connective tissue layer.
=== Trace gas analysis === Several techniques use ions created in a dedicated ion source injected into a flow tube or a drift tube: selected ion flow tube (SIFT-MS), and proton transfer reaction (PTR-MS), are variants of chemical ionization dedicated for trace gas analysis of air, breath or liquid headspace using well defined reaction time allowing calculations of analyte concentrations from the known reaction kinetics without the need for internal standard or calibration. Another technique with applications in trace gas analysis field is secondary electrospray ionization (SESI-MS), which is a variant of electrospray ionization. SESI consist of an electrospray plume of pure acidified solvent that interacts with neutral vapors. Vapor molecules get ionized at atmospheric pressure when charge is transferred from the ions formed in the electrospray to the molecules. One advantage of this approach is that it is compatible with most ESI-MS systems.
The Kisrawan campaigns were a series of Mamluk military expeditions against the mountaineers of the Kisrawan, as well as the neighboring areas of Byblos and the Jurd, in Mount Lebanon. The offensives were launched in 1292, 1300 and 1305. The mountaineers were Shia Muslim, Alawite, Maronite and Druze tribesmen who historically acted autonomously of any central authority. The Maronites in particular had maintained close cooperation with the last Crusader state, the County of Tripoli. After the fall of Tripoli to the Mamluks in 1289, the mountaineers would often block the coastal road between Tripoli and Beirut, prompting the first Mamluk expedition in 1292 under the viceroy of Egypt, Baydara. During that campaign, the Mamluks, spread along the coastal road and cut off from each other at various points, were constantly harried by the mountaineers, who confiscated their weapons, horses and money. Baydara withdrew his men only after paying off the mountain chiefs. In modern Lebanese historical narratives, the Kisrawan campaigns have been a source of controversy by historians from different religious groups. Maronite, Shia and Druze historians have each sought to emphasize the roles of their respective confessional group, over each other, in defending the autonomy of the Kisrawan from Mamluk outsiders. In writings by Sunni Muslim authors, the Mamluks are portrayed as the legitimate Muslim state working to incorporate Mount Lebanon into the rest of the Islamic realm.
Sources: en.wikipedia.org
The two substrates of this enzyme are prephenic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 4-hydroxyphenylpyruvic acid, carbon dioxide, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is prephenate:NADP+ oxidoreductase (decarboxylating). Other names in common use include prephenate dehydrogenase, prephenate (nicotinamide adenine dinucleotide phosphate), dehydrogenase, and prephenate dehydrogenase (NADP). This enzyme participates in phenylalanine, tyrosine and tryptophan biosynthesis.
== Further reading == Almond, Mark (2002). Uprising!: Ideological Shifts and Political Upheavals That Have Shaped the World. London: Octopus Publishing Group. ISBN 978-0-7607-3348-6. Garton Ash, Timothy (1990). The magic lantern: the revolution of '89 witnessed in Warsaw, Budapest, Berlin, and Prague. New York: Random House. ISBN 978-0-394-58884-1. Deletant, Dennis (1999). Romania under communist rule. Iasi: The Center for Romanian Studies. ISBN 978-973-98392-8-0. Gives a detailed account of the events in December 1989 in Timișoara. Engel, Jeffrey A. (2017). When the world seemed new: George H.W. Bush and the end of the Cold War. Boston; New York: Houghton Mifflin Harcourt. ISBN 978-0-547-42306-7. Ștefănescu, Domnița (1995). Cinci ani din istoria Romaniei: o cronologie a evenimentelor (decembrie 1989-decembrie 1994) [Five years of Romanian history: a chronology of events (December 1989-December 1994)] (in Romanian). Bucharest: Mașina de Scris. ISBN 978-9-73-971622-2. OCLC 909545436.
Blood glucose monitoring can be performed by multiple methods, such as the fasting glucose test which measures the level of glucose in the blood after 8 hours of fasting. Another test is the 2-hour glucose tolerance test (GTT) – for this test, the person has a fasting glucose test done, then drinks a 75-gram glucose drink and is retested. This test measures the ability of the person's body to process glucose. Over time the blood glucose levels should decrease as insulin allows it to be taken up by cells and exit the blood stream.
Sources: en.wikipedia.org
==== The cancelled meeting ==== In early December Thatcher had two ad hoc meetings with Heseltine, Brittan, Tebbit, William Whitelaw (Deputy Prime Minister), Geoffrey Howe (Foreign Secretary) and Nigel Lawson (Chancellor of the Exchequer). Howe and Tebbit were not unsympathetic to Heseltine's proposed consortium, and the decision was deferred to the Cabinet Economic Affairs Committee (E(A)) on Monday 9 December 1985. After that meeting Thatcher, who complained that three hours had been spent discussing a company with a market capitalisation of only £30m (a tiny amount in government terms), allowed Heseltine until 4pm on Friday 13 December to submit a viable proposal for a European deal. He did (with British Aerospace and GEC now part of his consortium), but Westland's directors rejected it. Heseltine had expected that there would be a second meeting of E(A) to discuss his consortium, but no such meeting was called; Thatcher later stated that the Monday meeting had agreed to leave the decision to Westland to take, but it later emerged that Ridley and Lord Young had placed such a meeting in their diaries and had been told by Number Ten that it had been cancelled. Heseltine threatened resignation for the first time. Heseltine raised his concerns with Tebbit, Whitelaw and John Wakeham (Chief Whip). At Cabinet on Thursday 12 December he had an angry exchange with Thatcher about the cancelled meeting, but Westland was not on the agenda for the meeting and Thatcher refused to permit a discussion on the matter, arguing that Cabinet could not do so without the necessary papers.
== Genetics == Fibrous protein, long filamentous protein molecule that forms one of the two main classes of tertiary structure protein Fusion protein, protein created through genetic engineering from two or more proteins Globular protein, one of the two main protein classes Protein family, group of evolutionarily related proteins Protein methods, techniques used to study proteins Protein subunit, single protein molecule that assembles with other protein molecules to form a multimeric or oligomeric protein Regulatory protein, term used in genetics to describe a protein involved in regulating gene expression
DMT binds non-selectively with affinities below 0.6 μmol/L to the following serotonin receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7. An agonist action has been determined at 5-HT1A, 5-HT2A and 5-HT2C. Its efficacies at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT2B receptor as two in vitro assays evidenced DMT's high affinity for this receptor: 0.108 μmol/L and 0.184 μmol/L. This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT2B receptor have been causally linked to valvular heart disease. It has also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline-1, and σ1 receptors. Converging lines of evidence established activation of the σ1 receptor at concentrations of 50–100 μmol/L. Its efficacies at the other receptor binding sites are unclear. It has also been shown in vitro to be a substrate for the cell-surface serotonin transporter (SERT) expressed in human platelets, and the rat vesicular monoamine transporter 2 (VMAT2), which was transiently expressed in fall armyworm Sf9 cells. DMT inhibited SERT-mediated serotonin uptake into platelets at an average concentration of 4.00 ± 0.70 μmol/L and VMAT2-mediated serotonin uptake at an average concentration of 93 ± 6.8 μmol/L.
== Research == In his research, White focused on membrane protein folding and stability, energetics of protein-bilayer interactions, experimentally determined hydrophobicity scales, translocon-assisted folding of membrane proteins, structure of fluid lipid bilayers, and MD simulations of lipid bilayers. His experimental expertise included X-ray diffraction, neutron diffraction, molecular dynamics simulations, calorimetry, physical chemistry, surface chemistry, statistical analysis of protein sequences, electrical impedance methods, planar bilayer methodology, peptide chemistry, and lipid chemistry. White’s lab determined the first fully resolved structure of a fluid lipid bilayer by combining x-ray and neutron diffraction data, and subsequently validated molecular dynamics simulations of fluid bilayers. White wrote a critical review of the principles of membrane folding and stability in 1999 that is among the ten most cited articles in Annual Review of Biophysics. Using a thermodynamic framework, he highlighted three main aspects of membrane protein folding energetics: protein binding and folding in bilayer interfaces, transmembrane helix insertion, and helix-helix interactions. In his paper “Mechanisms of Integral Membrane Protein Insertion and Folding” written in collaboration with Gunnar von Heijne, he evaluated the progress made during the past decade toward understanding translocon-assisted folding of membrane proteins and reviewed the role of basic thermodynamic principles in MP folding and assembly.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.